MDxHealth SA (NASDAQ:MDXH) Short Interest Up 84.1% in May

MDxHealth SA (NASDAQ:MDXHGet Rating) was the target of a significant growth in short interest during the month of May. As of May 31st, there was short interest totalling 15,100 shares, a growth of 84.1% from the May 15th total of 8,200 shares. Currently, 0.1% of the company’s stock are sold short. Based on an average trading volume of 52,700 shares, the days-to-cover ratio is presently 0.3 days.

MDxHealth stock opened at $7.63 on Monday. MDxHealth has a one year low of $6.61 and a one year high of $13.17. The company’s fifty day moving average price is $7.81 and its two-hundred day moving average price is $8.46.

MDxHealth (NASDAQ:MDXHGet Rating) last posted its earnings results on Wednesday, April 27th. The company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.55) by $0.50. The business had revenue of $6.11 million for the quarter, compared to analyst estimates of $8.85 million. On average, sell-side analysts predict that MDxHealth will post -2.09 EPS for the current fiscal year.

Separately, BTIG Research reaffirmed a “buy” rating and issued a $13.00 price target on shares of MDxHealth in a research note on Friday, April 29th.

Institutional investors have recently bought and sold shares of the business. Ghisallo Capital Management LLC acquired a new stake in shares of MDxHealth in the fourth quarter valued at about $190,000. Altium Capital Management LP acquired a new stake in shares of MDxHealth in the fourth quarter valued at about $344,000. Perkins Capital Management Inc. bought a new stake in shares of MDxHealth in the fourth quarter valued at about $857,000. Finally, Bleichroeder LP bought a new stake in shares of MDxHealth in the fourth quarter valued at about $18,643,000. 18.16% of the stock is currently owned by hedge funds and other institutional investors.

About MDxHealth (Get Rating)

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, the Netherlands, Belgium, Spain, Poland, Italy, rest of European Union, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications.

Further Reading

Receive News & Ratings for MDxHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MDxHealth and related companies with MarketBeat.com's FREE daily email newsletter.